EA201992303A1 - COMPOUNDS THAT INHIBIT Mcl-1 PROTEIN - Google Patents

COMPOUNDS THAT INHIBIT Mcl-1 PROTEIN

Info

Publication number
EA201992303A1
EA201992303A1 EA201992303A EA201992303A EA201992303A1 EA 201992303 A1 EA201992303 A1 EA 201992303A1 EA 201992303 A EA201992303 A EA 201992303A EA 201992303 A EA201992303 A EA 201992303A EA 201992303 A1 EA201992303 A1 EA 201992303A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compounds
protein
mcl
inhibit mcl
methods
Prior art date
Application number
EA201992303A
Other languages
Russian (ru)
Inventor
Пол Е. Харрингтон
Кейт Эштон
Шон П. Браун
Мэттью Р. Кэллер
Тодд Дж. Кон
Брайан Алан Лэнмэн
Кэсюэ Ли
Юньсяо Ли
Джонатан Д. Лоу
Ана Елена Минатти
Александер Дж. Пикрелл
Маркиан М. Стек
Джошуа Тейджерли
Original Assignee
Эмджен Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эмджен Инк. filed Critical Эмджен Инк.
Priority claimed from PCT/US2018/024723 external-priority patent/WO2018183418A1/en
Publication of EA201992303A1 publication Critical patent/EA201992303A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Abstract

В данном документе предусмотрены ингибиторы белка 1 клеток миелоидного лейкоза (Mcl-1), способы их получения, соответствующие фармацевтические композиции и способы их применения. Например, в данном документе предусмотрены соединения формулы (I)или их стереоизомер и их фармацевтически приемлемые соли и фармацевтические композиции, содержащие данные соединения. Соединения и композиции, предусмотренные в данном документе, могут применяться, например, в лечении заболеваний или состояний, таких как рак.In this document, protein 1 inhibitors of myeloid leukemia cells (Mcl-1), methods for their preparation, corresponding pharmaceutical compositions and methods for their use are provided. For example, compounds of formula (I) or a stereoisomer thereof and pharmaceutically acceptable salts and pharmaceutical compositions containing these compounds are provided herein. The compounds and compositions provided herein can be used, for example, in the treatment of diseases or conditions such as cancer.

EA201992303A 2017-03-30 2018-03-28 COMPOUNDS THAT INHIBIT Mcl-1 PROTEIN EA201992303A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762479230P 2017-03-30 2017-03-30
PCT/US2018/024723 WO2018183418A1 (en) 2017-03-30 2018-03-28 Compounds that inhibit mcl-1 protein

Publications (1)

Publication Number Publication Date
EA201992303A1 true EA201992303A1 (en) 2020-04-01

Family

ID=70546480

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992303A EA201992303A1 (en) 2017-03-30 2018-03-28 COMPOUNDS THAT INHIBIT Mcl-1 PROTEIN

Country Status (1)

Country Link
EA (1) EA201992303A1 (en)

Similar Documents

Publication Publication Date Title
PH12019502245A1 (en) Compounds that inhibit mcl-1 protein
PH12017500367A1 (en) Compounds that inhibit mcl-1 protein
CY1122566T1 (en) 6,7,8,9-TETPAYDP-3H-PYRAZOLO[4,3-F]ISOQUINOLINE DERIVATIVE USEFUL IN THE THERAPEUTIC TREATMENT OF CANCER
EA201891191A1 (en) 2-SUBSTITUTED HINAZOLIN COMPOUNDS CONTAINING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF THEIR APPLICATION
EA201891229A1 (en) EIF4A-INHIBITING COMPOUNDS AND RELATED METHODS
EA201790078A1 (en) MNK INHIBITORS AND RELATED METHODS
EA201891063A1 (en) DERIVATIVES OF DIHYDROIMIDAZOPIRAZINONE APPLICABLE IN THE TREATMENT OF CANCER
EA201692268A1 (en) PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS
EA201790779A1 (en) SUBSTITUTED AMINOPURIN COMPOUNDS, THEIR COMPOSITIONS AND METHODS OF TREATMENT USING SUCH CONNECTIONS
EA202192905A1 (en) COMPOUNDS CONTAINING N-METHYL-2-PYRIDONE AND PHARMACEUTICALLY ACCEPTABLE SALTS
EA201692481A1 (en) COMBINATION CONTAINING GLUCOCORTICOID AND EDO-S101
MX2019012847A (en) C5-anilinoquinazoline compounds and their use in treating cancer.
EA202191478A1 (en) HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS
EA202190588A1 (en) HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS
EA201890534A1 (en) NEW ANNELED PHENOXYCETAMIDES
EA202191548A1 (en) HUMAN PLASMA CALLICREIN INHIBITORS
EA201650003A1 (en) CYCLOALCYL-DIGETERO-CYCLIC DERIVATIVES
EA201891319A1 (en) COMPOUNDS OF ALKYDYDYDROCHINOLINSULPHONAMIDE
EA202191477A1 (en) HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS
EA201891680A1 (en) INDAN DERIVATIVES AS MGLUR7 MODULATORS
EA201992303A1 (en) COMPOUNDS THAT INHIBIT Mcl-1 PROTEIN
BR112018003335A2 (en) pharmaceutical compositions comprising 3- (5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl) -piperidine-2,6-dione
EA202190458A1 (en) COMPOSITIONS CONTAINING DENDREIMER
EA201990196A1 (en) Pyridopyrimidinone Inhibitors CDK2 / 4/6
EA201792265A1 (en) METHODS OF TREATING CARDIOVASCULAR DISEASES